WednesdayFeb 17, 2021 2:00 pm

Berkshire Biomedical Secures $3M in Funding for Development of Virtual Biometric Health Care System

Berkshire Biomedical, a medical equipment manufacturer based in Dallas, announced that it had acquired third-party funding totaling $3 million, which the company will use to advance the development of its prescription-drug and virtual-care management system. The system uses dual biometric authentication, which includes dental recognition. The biometric system is currently not available for commercial use but will be used to curb nonadherence to medication. The company states that medication nonadherence causes roughly 125,000 deaths in America each year and makes up nearly 10% of hospitalizations. The system’s main product is COPA, a computerized oral prescription administrator. COPA will help improve…

Continue Reading

WednesdayFeb 17, 2021 1:45 pm

New Imaging Test to Help Doctors Predict Cancer Patients Who Can Benefit from Hormone Therapy

Women who have cancer cells carrying estrogen receptors are usually given hormonal therapy as a targeted treatment. However, this treatment is not effective in all patients. However, a good method of accurately predicting which patients will benefit from the treatment and which will not hasn’t existed — until now. Enter a study conducted by researchers from the Washington University School of Medicine, St. Louis. The researchers have found that they can differentiate between patients who may or may not benefit from hormone therapy through the use of an imaging test that measures the estrogen receptor function in the patients’ cancer…

Continue Reading

TuesdayFeb 16, 2021 3:27 pm

United Medical Equipment Business Solutions Network Inc. Stands Ready to Address Swelling Market Need

Frequent, COVID-19 rapid tests could spur end of pandemic, make stay-at-home orders possible Countries turning to faster, more affordable tests to curb virus spread, enable economic recovery United Medical poised to capitalize on surging demand for rapid testing Frequent rapid testing could curb COVID-19 within weeks, a recent study published by the University of Colorado Boulder and Harvard University shows (https://ibn.fm/qmy42). Factors such as test turnaround-time and frequency are key in limiting the spread of the virus, making rapid tests one of the key tools for managing the virus outbreak. As such, the rapid tests are increasingly used in countries…

Continue Reading

TuesdayFeb 16, 2021 2:30 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Outlines 2021 Business Strategies for COVID-19 PCR Testing and Psychedelic Treatments

XPhyto Therapeutics Corp. plans to commercialize its rapid and portable PCR Kit this year to provide point-of-care diagnostics The company is confident about the successful validation of the PCR kit for the European commercial (CE-IVD) approval in Q1 2021 Hugh Rogers, CEO and Director of XPhyto, revealed in the latest news release that the company will make investments and development of psychedelic treatments XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator involved in the development of new pharmaceuticals, diagnostic products, and psychedelic medicine. As a part of its business strategy for the year 2021, the company…

Continue Reading

TuesdayFeb 16, 2021 11:37 am

MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) Plant-Based Biopesticide Achieves 100% Control of Root-Rot Disease in Recent Studies

Most recent tests show MustGrow’s patented biopesticide achieved 100% control over Aphanomyces within 24 hours Plant-based biopesticide uses natural defense mechanism found in mustard seed to control diseases, pests and weeds MustGrow hoping to provide valuable crop-protection tool for pulse-crop farmers MustGrow Biologics (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) has announced that its plant-based biopesticide has achieved 100% control of root-rot disease in a recent round of laboratory tests (https://ibn.fm/dmGPy). MustGrow, an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops such as fruits and vegetables, is focused on providing natural, science-based biological solutions to replace synthetic…

Continue Reading

FridayFeb 12, 2021 3:21 pm

CNS Pharmaceuticals (NASDAQ: CNSP) Celebrates IND Status, Prepares to Launch Brain Cancer Drug Trials

Brain cancer drug developer CNS Pharmaceuticals is celebrating recent news that the U.S. Food and Drug Administration (“FDA”) granted investigational new drug (“IND”) status to CNS Pharmaceuticals’ leading candidate for fighting glioblastomas Glioblastomas are a class of aggressive brain cancers with no known cure and a median life expectancy of 14 to 16 months following diagnosis The FDA’s decision to grant CNSP’s request for IND status clears the way for the company to begin human clinical trials within the next couple of months The company’s sublicensee partner, WPD Pharmaceuticals, will also prepare a first-ever Phase I trial for drug safety…

Continue Reading

FridayFeb 12, 2021 2:39 pm

Brain Scientific Inc. (BRSF) Establishing New Innovative Norms for Clinicians

Bergen Neurology Consultants utilized BRSF’s devices to improve patient care Minimal training means more staff can administer, monitor the EEG; more appointments can be scheduled Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company focused on developing innovative and proprietary medical devices and software, has created two devices designed to disrupt the EEG market. The NeuroCap(TM) and NeuroEEG(TM) offer cost-effective, disposable substitutes that help improve patient’s access to neurological care. The company is also helping improve the quality of care and solutions that practices can offer their patients. An example of the impact of the device can be seen through Bergen…

Continue Reading

FridayFeb 12, 2021 11:00 am

Development on Nasal Spray That Protects Against Common Cold, Coronavirus

Research on a new drug that prepares the respiratory tract immune system against infection and is currently being developed for the coronavirus has also shown its efficacy against rhinovirus. Rhinovirus is a common respiratory infection that is responsible for aggravating chronic obstructive pulmonary disease and chronic respiratory diseases such as asthma. This respiratory virus is also the primary cause of the common cold. The researchers found that treatment with the drug INNA-X before getting infected by the rhinovirus suppressed harmful inflammation and significantly decreased viral load. Associate professor Nathan Bartlett of the Hunter Medical Research Institute and the University of…

Continue Reading

ThursdayFeb 11, 2021 2:30 pm

Yale Researchers Develop Injection to Treat Skin Cancer

Researchers from Yale are developing an alternative treatment for skin cancer that will involve introducing nanoparticles into a cancerous tumor, thus eliminating the cancer cells in a two-stage approach. Vice chair and professor of dermatology at Yale School of Medicine Dr. Michael Girardi stated that for many patients, treating skin cancer was more important than finding an alternative but effective way to treat the disease using a simple method such as an injection. He explained that in dermatology finding an uncomplicated way to treat cancers of the skin such as basal cell carcinoma and squamous cell carcinoma was like finding…

Continue Reading

WednesdayFeb 10, 2021 2:45 pm

Covid-19 Antibodies Found in Placentas of Infected Pregnant Women

A group of researchers with the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia, have discovered antibodies of SARS-CoV-2 in the placentas of numerous women who had tested positive for the coronavirus in the course of their pregnancies. In the study, which was reported in the “Journal of the American Medical Association,” the researchers describe their results, which were derived from assessing various women who had been infected with the coronavirus as well as their placentas after they delivered their infants. Amid the pandemic, which has continued to infect millions of individuals across…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050